Evidence map›Paper›PMID 30680650›Full record

ArticleInflammopharmacology2019

Aberrant up-regulation of iNOS/NO system is correlated with an increased abundance of Foxp3

Sarra Benkhelifa, Hayet Rafa, Said Belhadef, Hayat Ait-Kaci, Oussama Medjeber, Mourad Belkhelfa, Sabah Hetit, Sonia Ait-Younes, Yvan De Launoit, Olivier Moralès and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Inflammopharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. The Antiproliferative Activity ofMolecules (Basel, Switzerland) · 2023
    Article
  7. Nanoliposome-Loaded Phenolics fromAnimals : an open access journal from MDPI · 2022
    Article
  8. Article
  9. iNOS Promotes the Development of Osteosarcoma via Wnt/Journal of immunology research · 2021
    Observational
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Sarra BenkhelifaTeam Cytokines and NO Synthases-Immunity and Pathogenesis, Laboratory of Cellular and Molecular Biology (LBCM), Faculty of Biological Science, University of Sciences and Technology (USTHB), BP 32 El-Alia Bab-Ezzouar, Algiers, Algeria.
Hayet RafaTeam Cytokines and NO Synthases-Immunity and Pathogenesis, Laboratory of Cellular and Molecular Biology (LBCM), Faculty of Biological Science, University of Sciences and Technology (USTHB), BP 32 El-Alia Bab-Ezzouar, Algiers, Algeria.
Said BelhadefOncology Service, Rouiba Hospital, Algiers, Algeria.
Hayat Ait-KaciAnatomical Pathology Service, Mustapha Pacha Hospital, Algiers, Algeria.
Oussama MedjeberTeam Cytokines and NO Synthases-Immunity and Pathogenesis, Laboratory of Cellular and Molecular Biology (LBCM), Faculty of Biological Science, University of Sciences and Technology (USTHB), BP 32 El-Alia Bab-Ezzouar, Algiers, Algeria.
Mourad BelkhelfaTeam Cytokines and NO Synthases-Immunity and Pathogenesis, Laboratory of Cellular and Molecular Biology (LBCM), Faculty of Biological Science, University of Sciences and Technology (USTHB), BP 32 El-Alia Bab-Ezzouar, Algiers, Algeria.
Sabah HetitDepartment of Gastroenterology, Issad Hassani Hospital (Beni-Messous), Algiers, Algeria.
Sonia Ait-YounesAnatomical Pathology Service, Nafissa Hamoud Hospital (Hussein-Dey), Algiers, Algeria.
Yvan De LaunoitInstitut de Biologie de Lille, UMR 8161, CNRS, Institut Pasteur de Lille, University of Lille, Nord De Lille, France.
Olivier MoralèsInstitut de Biologie de Lille, UMR 8161, CNRS, Institut Pasteur de Lille, University of Lille, Nord De Lille, France.
Hassen MahfoufOncology Service, Rouiba Hospital, Algiers, Algeria.
Nadira DelhemInstitut de Biologie de Lille, UMR 8161, CNRS, Institut Pasteur de Lille, University of Lille, Nord De Lille, France.
Chafia Touil-BoukoffaTeam Cytokines and NO Synthases-Immunity and Pathogenesis, Laboratory of Cellular and Molecular Biology (LBCM), Faculty of Biological Science, University of Sciences and Technology (USTHB), BP 32 El-Alia Bab-Ezzouar, Algiers, Algeria. touilboukoffa@yahoo.fr.
University of Sciences and Technology Houari Boumediene · DZCentre National de la Recherche Scientifique · FRHôpital Mustapha Pacha · DZInstitut de Biologie de Lille · FRUniversité de Lille · FR

Funding

national agency of research development in health (ATRSS) 03/06/01/10/011
6 · The paper itself

Abstract

Colorectal cancer (CRC) remains the most cancer type related to chronic inflammation; however, the mechanisms that link inflammation to CRC development and progression are still poorly understood. Our study aimed to investigate one of the prominent inflammatory response in cancers, iNOS/NO system. In this regard, we evaluated the link between the iNOS/NO system and CRC progression, its relation with the host immune responses and its response to cetuximab combined with chemotherapy. We found that the nitrite levels were nearly twice as high in metastatic CRC plasma and culture supernatants from PBMCs and tumor explants compared with those without metastases and healthy controls. Interestingly, we showed that the highest iNOS expression and NO levels are present in the damaged CRC tissues that have highest leukocyte infiltration. Our findings highlight the implication of iNOS/NO system in tissue alteration and leukocyte invasion. Thus, we observed imbalance between effector/memory T cell markers and Treg transcription factor (Foxp3). Accordingly, we detected higher IFNγ and T-bet expression levels in colorectal tumor tissues at early stage. In contrast, consistent with iNOS and Foxp3 expression, TGFβ, CTLA-4 and IL-10 were significantly related to the tumor stage progression. Furthermore, our study revealed that Cetuximab combined with chemotherapy treatment markedly down-regulates iNOS/NO system as well as IL-10 and TGFβ levels. Altogether, we conclude that cetuximab can potentiate the efficacy of chemotherapy, particularly by iNOS/NO system and immunosuppressive cytokines modulation. Thus, we suggest that iNOS/NO system may represent an attractive candidate biomarker for monitoring CRC progression, malignity and response to therapy.

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorCetuximabColorectal NeoplasmsDown-RegulationFemaleForkhead Transcription FactorsHumansImmunologic FactorsMaleMiddle AgedNitric OxideNitric Oxide Synthase Type IIT-Lymphocytes, RegulatoryBiomarkers, TumorCetuximabForkhead Transcription FactorsFOXP3 protein, humanImmunologic FactorsNitric OxideNitric Oxide Synthase Type IINOS2 protein, humanCetuximab and chemotherapyColorectal CancerHost immune responsesImmunomodulationiNOS/NO system

Identifiers

PMID30680650
OpenAlexW2911543526

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.